SI3340971T1 - Metode zdravljenja lennox-gastautovega sindroma z uporabo fenfluramina - Google Patents

Metode zdravljenja lennox-gastautovega sindroma z uporabo fenfluramina

Info

Publication number
SI3340971T1
SI3340971T1 SI201631816T SI201631816T SI3340971T1 SI 3340971 T1 SI3340971 T1 SI 3340971T1 SI 201631816 T SI201631816 T SI 201631816T SI 201631816 T SI201631816 T SI 201631816T SI 3340971 T1 SI3340971 T1 SI 3340971T1
Authority
SI
Slovenia
Prior art keywords
fenfluramine
methods
gastaut syndrome
lennox
treating
Prior art date
Application number
SI201631816T
Other languages
English (en)
Inventor
Stephen J. Farr
Bradley S. Galer
Original Assignee
Zogenix International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zogenix International Limited filed Critical Zogenix International Limited
Publication of SI3340971T1 publication Critical patent/SI3340971T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Paper (AREA)
  • Medicinal Preparation (AREA)
SI201631816T 2015-08-24 2016-08-24 Metode zdravljenja lennox-gastautovega sindroma z uporabo fenfluramina SI3340971T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562209090P 2015-08-24 2015-08-24
PCT/US2016/048470 WO2017035267A1 (en) 2015-08-24 2016-08-24 Methods of treating lennox-gastaut syndrome using fenfluramine
EP16840062.0A EP3340971B1 (en) 2015-08-24 2016-08-24 Methods of treating lennox-gastaut syndrome using fenfluramine

Publications (1)

Publication Number Publication Date
SI3340971T1 true SI3340971T1 (sl) 2024-05-31

Family

ID=58101064

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631816T SI3340971T1 (sl) 2015-08-24 2016-08-24 Metode zdravljenja lennox-gastautovega sindroma z uporabo fenfluramina

Country Status (17)

Country Link
US (2) US20170056344A1 (sl)
EP (1) EP3340971B1 (sl)
JP (1) JP6895949B2 (sl)
KR (3) KR102615486B1 (sl)
CN (3) CN115350168A (sl)
AU (1) AU2016312526B2 (sl)
BR (1) BR112018002046A2 (sl)
CA (1) CA2993665C (sl)
DK (1) DK3340971T3 (sl)
FI (1) FI3340971T3 (sl)
IL (1) IL257276B (sl)
LT (1) LT3340971T (sl)
MX (1) MX2018001435A (sl)
RU (1) RU2740919C2 (sl)
SI (1) SI3340971T1 (sl)
WO (1) WO2017035267A1 (sl)
ZA (1) ZA201800499B (sl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10647465B2 (en) 2010-11-12 2020-05-12 Niagara Bottling, Llc Perform extended finish for processing light weight ecologically beneficial bottles
EP2637831B1 (en) 2010-11-12 2018-09-05 Niagara Bottling, LLC Preform extended finish for processing light weight bottles
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
KR20180095674A (ko) 2015-12-22 2018-08-27 조게닉스 인터내셔널 리미티드 대사 저항성 펜플루라민 유사체 및 그 사용 방법
CN108883399B (zh) 2015-12-22 2021-06-22 周格尼克斯国际有限公司 芬氟拉明组合物及其制备方法
WO2018037306A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20180092864A1 (en) * 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
AU2018265353A1 (en) * 2017-05-09 2019-11-21 Zogenix International Limited Methods of treating Doose syndrome using fenfluramine
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
WO2019216919A1 (en) * 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
JP2021530481A (ja) * 2018-07-10 2021-11-11 ゾゲニクス インターナショナル リミテッド 肺高血圧症を有さない患者においててんかんまたはてんかん性脳症を処置するために使用するためのフェンフルラミン
US11597556B2 (en) 2018-07-30 2023-03-07 Niagara Bottling, Llc Container preform with tamper evidence finish portion
EA202191079A1 (ru) * 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
US20220133652A1 (en) * 2019-02-25 2022-05-05 Zogenix International Limited A formulation for improving seizure control
JP2022548892A (ja) 2019-09-17 2022-11-22 ゾゲニクス インターナショナル リミテッド てんかん患者をフェンフルラミンで治療する方法
US20210299064A1 (en) * 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888030A1 (en) * 2005-05-25 2008-02-20 Janssen Pharmaceutica N.V. Pediatric formulation of topiramate
US20070021501A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods of treating epileptogenesis
GB0515090D0 (en) * 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
BRPI0919876A8 (pt) * 2008-10-30 2016-02-10 Merck Sharp & Dohme Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.
AR079862A1 (es) * 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
CA2796963A1 (en) * 2010-04-23 2011-10-27 Piramal Enterprises Limited Nitric oxide releasing prodrugs of therapeutic agents
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
SI3035926T1 (sl) * 2013-08-19 2020-11-30 The Regents Of The University Of California Spojine in postopki za zdravljenje epileptičnih motenj

Also Published As

Publication number Publication date
LT3340971T (lt) 2024-04-25
ZA201800499B (en) 2018-12-19
CN115350168A (zh) 2022-11-18
KR20220025927A (ko) 2022-03-03
CA2993665A1 (en) 2017-03-02
MX2018001435A (es) 2018-04-20
AU2016312526A1 (en) 2018-02-22
WO2017035267A1 (en) 2017-03-02
IL257276A (en) 2018-03-29
US20200253895A1 (en) 2020-08-13
EP3340971A1 (en) 2018-07-04
DK3340971T3 (da) 2024-05-27
KR20230005426A (ko) 2023-01-09
BR112018002046A2 (pt) 2018-09-18
KR20180054584A (ko) 2018-05-24
JP6895949B2 (ja) 2021-06-30
CA2993665C (en) 2023-03-07
KR102481631B1 (ko) 2022-12-27
AU2016312526B2 (en) 2021-09-09
KR102615486B1 (ko) 2023-12-19
IL257276B (en) 2022-06-01
US20170056344A1 (en) 2017-03-02
CN115192575A (zh) 2022-10-18
RU2740919C2 (ru) 2021-01-21
CN108135865A (zh) 2018-06-08
RU2018108202A (ru) 2019-09-26
RU2018108202A3 (sl) 2020-01-20
JP2018525418A (ja) 2018-09-06
EP3340971B1 (en) 2024-03-13
EP3340971A4 (en) 2019-05-01
FI3340971T3 (fi) 2024-06-10

Similar Documents

Publication Publication Date Title
IL257276B (en) Methods for treating Lennox-Gastaut syndrome using fenforamine
HK1251409A1 (zh) 治療癌症的方法
ZA201804227B (en) Methods of treating cancer
ZA201907168B (en) Methods of treating doose syndrome using fenfluramine
ZA201706257B (en) Treatment of wood
HK1248552A1 (zh) 使用川地匹坦的治療方法
HK1244217A1 (zh) 用於治療蛋白質病的方法
IL256207B (en) Methods for treating multiple sclerosis
HK1258611A1 (zh) 腹水的治療
HK1246655A1 (zh) 治療不育的方法
ZA201808607B (en) Methods of treating prader-willi syndrome
EP3325006A4 (en) METHOD FOR TREATING CD166-EXPRESSIVE CANCER
HK1255221A1 (zh) 使用卡多曲組合物進行治療的方法
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
EP3491129A4 (en) METHODS OF TREATING OSMIDROSIS
IL254336A0 (en) A new treatment method
GB201512139D0 (en) Methods of treatment
PT3261661T (pt) Menotropina para tratar a infertilidade
AU2015905220A0 (en) Methods of treatment
GB201511017D0 (en) Method of treatment
GB201505633D0 (en) Novel treatment of STIs
AU2015900498A0 (en) Method of treatment